Abstract

LeMaitre Vascular will report second-quarter 2026 results on August 4, 2026, Post Market, with investors tracking revenue, margin trajectory, and adjusted EPS as projections indicate continued double‑digit growth and operating leverage building on the first-quarter performance.

Market Forecast

Consensus models point to second-quarter revenue of 70.97 million US dollars, up 13.59% year over year, alongside estimated adjusted EPS of 0.81, up 42.38% year over year, and EBIT of 21.38 million US dollars, up 40.49% year over year. The core franchise is expected to maintain a double‑digit top-line pace this quarter, supported by steady procedural volumes and firm pricing; within the portfolio, management and analysts continue to highlight endovascular and dialysis access products as prospective outperformance areas, with growth expected to exceed the company-wide 13.59% year-over-year revenue increase, though the company has not issued segment-level revenue guidance for the quarter.

Last Quarter Review

In the first quarter of 2026, LeMaitre Vascular delivered revenue of 66.55 million US dollars, up 11.16% year over year, with a gross profit margin of 72.72%, GAAP net profit attributable to shareholders of 15.68 million US dollars, a net profit margin of 23.56%, and adjusted EPS of 0.68, up 41.67% year over year. An efficiency-driven operating cadence lifted EBIT to 17.78 million US dollars, up 40.78% year over year, while GAAP net profit increased sequentially by 0.62%, and adjusted EPS exceeded the model by 0.02. Company-wide, the revenue base advanced 11.16% year over year to 66.55 million US dollars on broad-based product demand and disciplined pricing, with the quarterly outperformance primarily attributable to higher volumes and operating leverage rather than mix shift.

Current Quarter Outlook (with major analytical insights)

Main business: revenue cadence and margin trajectory

The near-term narrative revolves around whether LeMaitre Vascular can translate its first-quarter operating leverage into sustained second-quarter margin performance as revenue scales to an estimated 70.97 million US dollars, up 13.59% year over year. The first-quarter gross profit margin of 72.72% establishes a high bar; preservation or modest expansion likely depends on product mix and price discipline, while temporary headwinds may stem from manufacturing mix, inventory normalization, and freight. EBIT is projected at 21.38 million US dollars, up 40.49% year over year, implying continued scaling of operating efficiency as expenses grow more slowly than revenue; if realized, this would underpin the 0.81 adjusted EPS forecast, up 42.38% year over year. From a cadence standpoint, second quarters often benefit from normal seasonality and fuller selling days compared with the first quarter, which may assist throughput and absorption. Given first-quarter net margin of 23.56% and the step-up in EBIT implied for the second quarter, incremental margin capture is attainable if price and mix hold and if operating expense growth remains in line with plan. With no explicit gross margin or net margin guidance disclosed in the dataset, the key watch item is operating discipline: a flat to modestly higher gross margin combined with contained growth in SG&A and R&D would align with the strong EPS trajectory implied by the projections. Cash conversion and working capital management will also matter to investor interpretation of results. Sustained top-line growth with proportionate inventory turns and stable receivables days can reinforce confidence in the scalability of the model. Should inventory normalize faster than anticipated, it could modestly dampen gross margin in the short term due to absorption dynamics but improve cash flow, a tradeoff markets typically accept when visibility on demand remains solid.

Most promising business: endovascular and dialysis access products

Within the company’s product range, endovascular and dialysis access lines remain the focal areas for incremental growth given ongoing procedure adoption and cross-selling opportunities through the established sales channel. The company has not issued segment-level revenue guidance for the second quarter; nevertheless, analyst commentary and model assumptions imply these categories are positioned to outpace the company-wide revenue growth estimate of 13.59% year over year, driven by consistent utilization in hospital settings and the breadth of the sales footprint. In practice, the growth algorithm for these lines blends steady unit expansion, modest price resilience, and continued penetration of accounts that have already adopted complementary products, enabling share-of-wallet gains without dependence on single large tenders. Newer product variants and line extensions can contribute incremental lift by expanding indications and offering workflow advantages, which can be decisive factors in physician preferences at the point of use. Because much of the company’s revenue is generated by direct sales teams, execution quality—call frequency, clinical education, and post‑sales support—remains a lever for pace of wins and expansions. In quarters when training calendars and scientific meetings cluster, well-timed launches and case support can improve conversion metrics, reinforcing a stronger mix from higher-value devices. Gross margin dynamics in these growth categories are usually favorable owing to differentiated designs and stable pricing environments. If product costs remain on plan and no unusual inventory transitions occur, the contribution margin from endovascular and dialysis access should support the second-quarter EBIT expansion implied by estimates. Segment-level upside will depend on the cadence of procedural volumes and any regional hospital purchasing trends; nonetheless, the qualitative setup suggests a constructive skew for these categories this quarter.

Key stock price drivers this quarter: beats, operating leverage, and guidance tone

The first driver is the probability of top- and bottom-line beats relative to the 70.97 million US dollars revenue and 0.81 adjusted EPS projections. A modest revenue beat combined with maintained gross margin near the first-quarter’s 72.72% could translate into outsized EPS outperformance given the operating leverage evident in the first quarter. Conversely, if price mix softens or temporary cost items surface, the EPS outturn could hew closer to consensus even if revenue meets projections. A second driver is the durability of operating leverage. The first quarter saw EBIT grow 40.78% year over year on an 11.16% revenue gain, an expression of fixed-cost leverage as scale increases. The degree to which second-quarter EBIT growth approximates the 40.49% forecast will guide investors on the sustainability of this leverage into the back half of 2026. Any acceleration in hiring or commercialization expenses around pipeline initiatives may temper near-term EBIT flow-through but can be perceived constructively if tied to high-confidence launches or geographic expansions. The third driver is guidance tone for the remainder of the year. If management reaffirms or raises full-year expectations following second-quarter performance, the market may ascribe higher confidence to the multi-quarter earnings trajectory. Clarity on expense growth lanes and capital allocation—specifically dividends, share repurchases, or opportunistic bolt-on acquisitions—can also influence how investors extrapolate margin frameworks into 2027. Finally, commentary on order patterns, hospital throughput, and any regional demand variations will be monitored closely, as these often foreshadow third-quarter cadence.

Beyond these top drivers, investors will parse color on FX exposure and international demand. Modest currency headwinds or tailwinds can affect translated revenue without materially altering underlying volume trends, but they may still influence near-term reported growth versus constant-currency baselines. The sales channel’s productivity metrics, including territory coverage and account penetration, will be useful to evaluate whether sequential gains reflect sustainable expansion. Furthermore, inventory and logistics updates—especially where freight normalization or supplier lead times are improving—can either bolster near-term gross margin or set a cleaner base for the second half. On the innovation side, updates on product enhancements and regulatory milestones will help frame medium-term growth. While not typically a single-quarter swing factor, consistent progress in trials, clearances, or label expansions can solidify conviction in continued revenue compounding. Lastly, the cash generation profile remains a valuation anchor; steady operating cash flow that tracks earnings and supports disciplined reinvestment can validate the higher EPS growth implied in the current quarter’s forecast.

Analyst Opinions

The balance of recent institutional commentary skews bullish, with a ratio of 3 bullish to 0 bearish views. One well-followed analyst maintained a Buy rating with a 115.00 US dollars price target, citing confidence in the company’s earnings power as revenue compounds through both price and volume. Another reiterated a Buy with a 110.00 US dollars target, emphasizing sustained double‑digit revenue growth potential and execution consistency across product categories. A third institution lifted its target to 120.00 US dollars while maintaining an Outperform stance, underscoring the prospects for continued margin expansion and the likelihood of upward earnings revisions if operating leverage persists. In synthesizing these views, the market’s constructive stance is tied to several identifiable threads that closely align with second-quarter setup. First, there is an expectation that revenue growth near the projected 13.59% year over year is achievable, anchored by stable hospital utilization and the breadth of the product offering. Second, analysts point to gross margin resilience—72.72% in the first quarter—as a credible baseline, suggesting that even modest revenue upside can flow through efficiently to EBIT, which consensus pegs at 21.38 million US dollars for the quarter. Third, the recent track record of beating EPS expectations—0.68 versus a 0.66 model in the first quarter—bolsters confidence that the projected 0.81 can be met or exceeded if volume and mix trends hold. The constructive case also highlights qualitative supports: an established direct sales infrastructure that continues to deepen account penetration, line extensions that expand the clinical toolkit for customers, and ongoing operational discipline that tempers expense growth relative to sales. Analysts note that while the company has not provided segment-level targets for the quarter, the areas flagged as incremental growth engines—endovascular and dialysis access—remain positioned to outgrow the total company, aiding the overall mix and margin contour if realized. Looking beyond the print, a steady cadence of product enhancements and the potential for selective tuck-in deals are seen as catalysts for sustaining the multiyear earnings trajectory. From a risk-balance perspective, the majority view acknowledges typical execution and macro variables—pricing dynamics, hospital purchasing patterns, and FX translation—but sees these as manageable within the current quarter’s framework. As a result, the focus remains on margin progression and the tone of any updates to the full-year outlook. Should management signal confidence in maintaining double‑digit revenue growth with expanding EBIT, bullish analysts expect models to migrate higher, reinforcing the favorable bias heading into the second half of 2026. In summary, the prevailing institutional perspective is constructive because it pairs a transparent top-line model—70.97 million US dollars of second-quarter revenue, up 13.59% year over year—with a cost structure that is already demonstrating operating leverage. If the gross margin base near the first-quarter’s 72.72% is sustained and expenses remain on plan, the implied 0.81 adjusted EPS appears attainable, with upside skew contingent on mix and incremental sales execution. This view, echoed across recent notes, supports a majority-bullish stance into the announcement on August 4, 2026, Post Market.